



Alfasigma: company presentation

A 70-year success story — Founded in 2015 through the merger of the Alfa Wassermann and Sigma-Tau groups — two of Italy's historic pharmaceutical companies — Alfasigma is one of the key players in the Italian pharmaceutical industry. Nationally, it is one of the top five Italian-owned pharmaceutical companies and is broadly represented on the international market, not only in terms of quantity of products, but also because it can count on a large number of subsidiaries and affiliated companies as well as a network of distributors that guarantee its diffusion throughout all five continents and in nearly 90 countries worldwide.

With the recent acquisition in Italy of Sofar S.p.A., Alfasigma steadies its leadership in the gastrointestinal area and in the research on microbiota by aiming to expand its presence in the international market.

Our passion, our talents — These include 3000 employees, about half of whom are connected to the sales force and almost 60% are located in Italy. They are divided into different locations: Bologna is home to the management centre and Milan holds the international division, while Pomezia (Rome), Alanno (Pescara) and Sermoneta (Latina) and Trezzano Rosa (MI) house the production facilities. Bologna and Pomezia and the Kilometro Rosso Science and Technology Park in Bergamo also host the Research & Development laboratories.

In addition to the Italian plants, Alfasigma also has two other production plants — one in Tortosa, Spain, the other in Shreveport, Louisiana, USA. The corporate turnover for 2021 exceeded one billion euros, evenly split between Italy and the rest of the world. In addition to Alfasigma's 17 direct subsidiaries and those of the newly acquired Sofar, presence in the rest of the world is guaranteed by first-class local and international distributors.

Excellence in research, a corporate core business — The company is one of the pharmaceutical companies in Italy making the highest investment in Research and Development, concentrating particularly in vascular and gastrointestinal research.

On the 14th of September 2021 the *LABIO 4.0 Marino Golinelli* Technological Development Centre in Pomezia was inaugurated, which will enable the company to achieve new goals and innovations for the pharmaceutical industry. The site hosts the new Research & Development laboratories dedicated to pharmaceutical technology and analytical chemistry with an investment of over 17 million euros. This is where all of the site's Research & Development structures will be concentrated. In the same pavilion, a pilot plant is also being built for the production of experimental drugs, to operate in synergy with all Alfasigma technical and scientific functions. The other R&D centre is located in the historical headquarters of Bologna.

Furthermore, Alfasigma also makes use of the laboratories located at the Kilometro Rosso Science and Technology Park in Bergamo (SOFAR), a center of excellence in microbiota research.

ALFASIGMA S.p.A.
Capital Stock € 10.000.000,00
R. C. and Tax Code -
P.IVA/VAT IT 03432221202

Registered Office & Headquarters
I – 40133 BOLOGNA
Via Ragazzi del '99, 5
Ph. +39 0516489511
Fax +39 051388593

International Division
I – 20124 MILANO
Via Fabio Filzi, 29
Ph. +39 02642221
Fax +39 0264222344

Manufacturing Plant
I – 65020 ALANNO (PE)
Via Enrico Fermi, 1
Ph. +39 08585711
Fax +39 0858541625

Manufacturing Plant
I – 00071 POMEZIA (RM)
Via Pontina, Km 30,400
Ph. +39 0691391
Fax +39 0691393980

Therapeutic areas and products — In Italy the company focuses on prescription specialties, over-the-counter drugs, nutraceuticals and dietary supplements; in addition, it is also present in many primary care therapeutic areas. Among the well-known over-the-counter products are Biochetase, Neo-Borocillin, Dicloream, Proctosoll and other commonly known names such as Yovis, Carnidyn and Tau-Marin.

The two main therapeutic areas are gastrointestinal and vascular covered by two of the company's five proprietary molecules; Rifaximin and Sulodexide.

To date, gastroenterology is the Group's most important sector thanks, above all, to Rifaximin- α , an antibiotic for the treatment of gastro-intestinal pathologies which is an intellectual property entirely the result of Alfasigma research.

As for the vascular area, the two drugs are: Sulodexide, a Vessel brand heparinoid which, besides being one of the company's first patents, it is marketed in over 40 countries; Parnaparin, a Fluxum-brand heparin used to prevent deep vein thrombosis, another product originating from internal research.

Other areas in which the company is present are: dermatology, orthopaedics and rheumatology, the cardio-metabolic area, COPD, gynaecology, diabetology.

In the US, a focus on nutraceuticals was added following the acquisition of PamLab from Nestlé Health Science.

The recent Sofar acquisition will lead to the expansion of Alfasigma's product range in Italy and in foreign markets, adding to its portfolio SOFAR's products: Pentacol, Enterolactis and Gerdoff for the gastrointestinal area; Cistiflux and Siler for the gynecological/urological area.

At the patients' side, both in Italy and around the world — Alfasigma's focus remains on the patients, thus it is strongly committed to manufacturing and marketing innovative solutions that meet the medical needs of thousands of people suffering from diseases that have not yet been overcome. One of these is malaria, which still claims millions of lives in third world countries.

Outside of Italy the company focuses mainly on the marketing of proprietary molecules, such as the molecule Eurartesim, one of the most widely used drugs for the treatment of malaria, combining dihydroartemisinin and piperaquine, developed and produced in Alfasigma Italian plants, a molecule discovered and developed also thanks to the research of Tu Youyou, a Chinese scientist who won the Nobel Prize for medicine in 2015. Eurartesim is distributed in third world countries at an affordable price through the Bill & Melinda Gates Foundation.

A starring role, even on the international market — Alfasigma's global turnover exceeds one billion euros and half of this is the result of exports, which are constantly on the rise.

In the last years, despite the serious pandemic caused by COVID-19, Alfasigma had no problems in maintaining the supply and availability of critical products for the health of our patients.

Alongside the traditional business, the company has become a leading player with a division dedicated to Contract Manufacturing — that is, the manufacture of products for other multinational and Italian pharmaceutical companies — an area that rewards excellence in quality and service: since 2017 this area has shown a CAGR (Compound Annual Growth Rate) of 10.2%.

The value of sustainability — For years Alfasigma has been attentive and close to the territories and communities where it operates, supporting social, cultural and philanthropic projects and initiatives.

In the communities where the company is present, many non-profit organisations benefit from corporate contributions, including Fondazione Teatro Comunale di Bologna, Fondazione Golinelli, ANT (the Italian National Tumour Association) and many others.

Today, Fondazione Golinelli, founded in Bologna in 1988, is a unique example in Italy of a fully operational private foundation, inspired by the American model of philanthropic foundations. In an integrated manner, it deals with education, training and culture to promote the intellectual and ethical growth of young people and the general society with its aim being to contribute to the sustainable development of our country.

For Alfasigma, passion means a constant commitment to supporting and sustaining culture, art and science because it believes that one's well-being does not depend solely on being healthy but also derives from other aspects of life and the surrounding environment.

Commitment to patients, pharmacists and doctors — Alfasigma is engaged in campaigns to raise awareness in different therapeutic areas, in particular, cirrhosis of the liver, cardiovascular diseases, diabetes, chronic obstructive pulmonary disease, malaria, rheumatoid arthritis and psoriasis.

In addition to raising public awareness, working in close collaboration with scientific societies and patient associations, Alfasigma supports numerous continuing medical education (CME) courses for pharmacists and physicians in Italy and worldwide.

The well-being of our employees — The company is strongly motivated to create a healthy, challenging and competitive work environment applying pharmaceutical industry best practices. An environment where its employees can feel comfortable and motivated to express their fullest potential.

Among the initiatives focused on employees are cultural events with free admission, such as visits to exhibitions and participation in concerts. Alfasigma also provides company welfare packages and, since 2019, also the so-called remote working, i.e. the possibility of working from home for a set number of days to meet individual needs.

The company is developing environmental awareness and sustainability initiatives in areas where it has administrative and production facilities.

Media Relations

CorporateCommunication@alfasigma.com

www.alfasigma.com

Last update, November 2022.